Xeris Biopharma COO McCulloch sells $141,120 in shares

Kevin McCulloch, the President and COO of Xeris Biopharma Holdings, Inc., divested 15,000 shares of the company's stock on October 1, 2026. The sale, conducted under a Rule 10b5-1 plan established on September 4, 2025, yielded a total of $141,120, with the shares exchanged at prices ranging from $9.180 to $9.665, resulting in a weighted average price of $9.408.

The stock, which has climbed to $10.46, reflecting a 75% increase over the last six months, now trades above its fair value, categorizing it among overvalued stocks. McCulloch, who now directly owns 1,599,208 shares of the company, has disclosed that his spouse indirectly holds 25,000 shares, though McCulloch disclaims any beneficial ownership beyond his financial interest.

Xeris Biopharma reported a revenue of $92.1 million for its second quarter of 2026, exceeding analysts' expectations, but the company reported a loss of $0.18 per share, deviating from the anticipated profit of $0.01. Despite the revenue surge, investors were primarily concerned with the earnings shortfall and a one-time non-cash GAAP charge linked to convertible note remeasurement.

Oppenheimer maintained an "Outperform" rating on Xeris Pharmaceuticals, setting a price target of $18.00, following a virtual presentation about XP-8121, a novel subcutaneous levothyroxine therapy for hypothyroidism intended for millions of U.S. patients still unresponsive to conventional oral treatment.